Just a few neoantigens may be enough for T cells to control

In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.

Neoantigen Cancer Vaccines & Companies Bringing it to the Market: Next Big Immunotherapy Breakthrough

How do cancer vaccines work?

B cells and CD4+ T cells are the stage crew for antitumor immunity

Harnessing the Immune System To Treat Cancer

The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells, Molecular Cancer

Weekly Digests for April 2020

Frontiers Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy

The Many Hats of Neoantigen Peptides in Precision Medicine

The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells, Molecular Cancer

Tumor Antigen Targets for Personalized Adoptive T Cell Therapies